Floatz logo

Selinexor

Myelodysplastic Syndrome

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

295 Active assets in the Myelodysplastic Syndrome cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Sawa Ito, MD
Phase 4BB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 4BB
Daunorubicin
OHSU Knight Cancer Institute
Phase 3BB
FILGRASTIM
City of Hope Medical Center
Phase 4BB
Idarubicine
OHSU Knight Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Selinexor is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
mantle cell lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →